Deutsch | English | Español | Français | Italiano | Português | Русский | العربية | 日本語 | 简体中文 | 繁體中文 | 한국의 | Türk | Polski
LOGO
Global B2B Portal for Bio-Medical & Pharm Industry
Product / Service Supplier Catalogs & Literature    
Search
or
home Product News Catalogs Web TV News & Topics Featured Articles Trade Shows Sourcing Help My allbiomedical
News & Topics Content
allbiomedical > News & Topics >Bristol-Myers and Innate Pharma to Develop Cancer Drug

Bristol-Myers and Innate Pharma to Develop Cancer Drug
Author: Drug Discovery & Development Staff
Source From: Drug Discovery & Development
Posted Date: 2011-07-13

Bristol-Myers Squibb Company and Innate Pharma S.A. announced a global agreement for the development and commercialization of IPH2102, a novel antibody in Phase I development for the treatment of cancer.

Under the terms of the agreement, Innate Pharma will grant to Bristol-Myers Squibb exclusive worldwide rights to develop, manufacture, and commercialize IPH2102 and related compounds blocking KIR receptors.

The agreement covers all potential indications for IPH2102. Innate Pharma will continue to develop IPH2102 in acute myeloid leukemia (AML) through the end of Phase II. Innate Pharma will also provide preclinical support for the development of IPH2102.

Bristol-Myers Squibb will fund the development of IPH2102, make an upfront payment of $35 million and additional payments of up to $430 million, depending on the achievement of pre-specified milestones during the development and commercialization period, as well as pre-specified tiered double-digit royalty payments on worldwide net sales.

 

Tags:

Original Hyperlink: http://www.dddmag.com/Bristol-Myers-and-Innate-Pharma-to-Develop-Cancer-Drug-071..

For more information from this magazine/website? Please click here http://www.dddmag.com

About Us:Drug Discovery & Development magazine delivers insight into the full landscape of technologies, tools, and business/regulatory strategies that help scientists and executives accelerate the pace and productivity of drug research and development. Articles are concise, with practical intent: to present information for day-to-day technical and business decision-making.

Note: The copyright and the ownship of the brand, product names, product numbers, and content mentioned belongs to their repective companies.

Latest News

‧2012-11-23
European semis make European industry competitive?

‧2012-11-13
Medical Devices Market in China Will Maintain 20 % AGR

‧2012-09-21
The European Market: What Can You Do For Your Country?

‧2012-05-14
U.S. Jobless Claims Fall for Second Week

‧2012-04-05
Thomas Reuters Annouced 2012 100 Top Hospital of America

Related Catalogs
Featured Pages
Contents
· Home
· Product News
· Catalogs
· Web TV
· News & Topics
· Features Articles
· Trade Show
· Sourcing Help
· My Allbiomedical
Special Zone
· Directory
· Trade Show Supplement
Allbiomedical.com
· About Us
· Promote Your Business
· Advertise
· Partner with Us
· Press Release
· Contact Us
· Term of Use
· Privacy Policy
· Starter Program
· Sitemap
B2B Web Portal Alliance
· Allitwares.com
· Allmetalworking.com
· Allbiomedical.com
· Allautowares.com
Buy Engineer Sample Kits
OEM Sourcing
Language
· Deutsch
· English
· Español
· Français
· Italiano
· Português
· Русский
· العربية
· 日本語
· 简体中文
· 繁體中文
· 한국의
· Türk
· Polski
 
   

Copyrights © 2012 Allitwares Corporation All Rights Reserved. www.allbiomedical.com is a Division of Allitwares Corporation
www.allbiomedical.com is a B2B Trade Portal | B2B Web Portal |B2B Marketplace for biomedical and pharmaceutical industry